Barclays’s Greenwich LifeSciences GLSI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$27.8K Sell
1,159
-8,585
-88% -$224K ﹤0.01% 4501
2025
Q4
$205K Buy
9,744
+1,030
+12% +$10.8K ﹤0.01% 4295
2025
Q3
$86.7K Sell
8,714
-1,868
-18% -$21.1K ﹤0.01% 4650
2025
Q2
$96K Buy
10,582
+3,949
+60% +$37.6K ﹤0.01% 4585
2025
Q1
$63.3K Sell
6,633
-3,015
-31% -$36.6K ﹤0.01% 4557
2024
Q4
$108K Buy
9,648
+1,088
+13% +$14.6K ﹤0.01% 4576
2024
Q3
$123K Buy
8,560
+6,538
+323% +$96.9K ﹤0.01% 4516
2024
Q2
$34.9K Buy
+2,022
New +$29.5K ﹤0.01% 4329
2022
Q2
Sell
-665
Closed -$13K 5117
2022
Q1
$13K Buy
+665
New +$13.4K ﹤0.01% 4549

Other funds holding GLSI

Barclays's GLSI Position: Q1 2026 in Review

Barclays reduced its Greenwich LifeSciences (GLSI) stake by 88% in Q1 2026, selling an estimated $224K and leaving 1,159 shares worth $27.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4501.

Barclays first reported a position in GLSI in Q1 2022 and has held it in 9 quarters since. The position peaked at $205K in Q4 2025. 64 funds tracked by Wall St. Rank hold GLSI as of Q1 2026.

  • Barclays held 1,159 shares of Greenwich LifeSciences worth $27.8K as of Q1 2026.
  • Barclays sold 8,585 Greenwich LifeSciences shares in Q1 2026, an estimated $224K.
  • Greenwich LifeSciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4501 holding.
  • Barclays first reported a position in Greenwich LifeSciences in Q1 2022 and has held it in 9 quarters since.
  • Barclays's Greenwich LifeSciences position peaked at $205K in Q4 2025.
  • 64 funds tracked by Wall St. Rank held Greenwich LifeSciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.